Introduction
Anti-tubular basement membrane (anti-TBM) antibody nephritis is a very uncommon disease associated with autoantibodies to a non-collagenous 54 to 58 kD protein in proximal tubular basement membranes (TBMs), called tubulointerstitial nephritis antigen (TIN-ag). 1 , 2
The disease might be idiopathic or due to secondary causes and could present in an acute or chronic setting. 1 , 2 Secondary etiologies of anti-TBM could be due to lupus nephritis, drug-induced interstitial nephritis, pyelonephritis, acute rejection of kidney allograft, or post-bone marrow transplant. It is also associated with membranous nephropathy or other renal disorders, such as anti-glomerular basement membrane (anti-GBM) antibody disease. 1 The primary diagnostic characteristics of anti-TBM antibody nephritis include marked interstitial nephritis featuring lymphoplasmacytic infiltration with occasional neutrophils, acute and chronic tubular injury, linear deposition of IgG and complement C3 along TBMs present by immunofluorescence microscopy, and detection of anti-TBM antibodies in the serum. 2 , 3 This report describes a case of a patient with a history of cutaneous basal cell carcinoma, adenocarcinoma of the prostate, and chronic lymphocytic leukemia (CLL) who was subsequently diagnosed with chronic kidney disease due to anti-TBM antibody nephritis.
Case Presentation
A 69-year-old male with a past medical history of hypertension, cutaneous basal cell carcinoma, and prostatic adenocarcinoma treated with proton therapy and leuprolide visited his oncologist as a follow-up for his recently diagnosed CLL. A nephrology consultation was sought due to the progressive worsening of kidney function. At the time of consultation, serum creatinine (Cr) was 2.5 mg/dL, compared with his baseline Cr of 1.1 mg/dL 3 months prior with mild non-anion gap metabolic acidosis. The patient was not on any medications at that time. There was no history of urinary retention or obstructive uropathy. A computed tomography (CT) scan revealed a homogenously enhanced soft tissue mass in the mediastinum and retroperitoneum, measuring 9.7 × 8.3 cm. This mass was suspected of lymphoma, encasing vital structures such as aorta, celiac axis, superior mesenteric artery, and renal arteries and partially involving the inferior vena cava. Initial differential diagnosis included monoclonal gammopathies, tumor lysis syndrome, and renal ischemia resulting from the encasement of renal arteries by the tumor. Laboratory results were normal for serum uric acid, lactate dehydrogenase, phosphorus, and calcium levels, making tumor lysis syndrome less likely. Serologies for anti-nuclear antibody (ANA), anti-dsDNA and anti-GBM antibodies, cryoglobulins, and anti-neutrophil cytoplasmic antibody (ANCA) panel were also negative. Serum protein electrophoresis (SPEP) with immunofixation revealed an IgG lambda light chain band. Urine protein electrophoresis (UPEP) disclosed a small gamma spike measuring 5 mg/dL, raising suspicion for monoclonal gammopathy or multiple myeloma. Serum levels of IgA, IgG, IgM, and C3 were normal, and C4 was low (8.9 mg/dL).
A urine dipstick test showed proteinuria and glycosuria despite no prior history of diabetes mellitus. A spot urine protein to Cr ratio (UPCR) was 773 mg/g. Renal ultrasound demonstrated normal kidney size and echogenicity without any signs of hydronephrosis. The patient’s serum Cr level continued to rise, reaching 3.6 mg/dL 2 months post-initial consultation, prompting the decision to proceed with a kidney biopsy.
The initial pathology examination indicated the presence of 27 glomeruli, with 7 (22%) being obsolescent. The non-sclerosed glomeruli showed focal modest mesangial expansion and focal segmental glomerulosclerosis. There was extensive interstitial fibrosis and tubular atrophy (IFTA), involving approximately 90% of cortical parenchyma, accompanied by mild interstitial edema, focal tubulitis, and patchy interstitial lymphoplasmacytic inflammation ( Figure 1A ). Renal parenchymal involvement by lymphoma was ruled out by immunohistochemical stains for CD3, CD20, PAX5, CD5, and CD23. Immunofluorescent microscopy displayed linear staining of most TBMs for polytypic IgG with no kappa/light chain bias, C3, and focally for C1q. No staining of glomerular or Bowman’s basement membranes was evident ( Figure 1B ). Electron microscopy did not reveal any immune deposits in the glomeruli or TBMs ( Figure 1C and D). There was no evidence of a paraprotein-related nephropathy by light, immunofluorescent, or electron microscopy. Altogether, the findings were interpreted as anti-TBM antibody nephritis with prominent chronicity with an element of ischemic nephropathy, likely related to the mass encasing renal arteries.
The R-CVP (rituximab-cyclophosphamide, vincristine, prednisone) cycle of chemotherapy, along with filgrastim injection, was initiated to reduce the mass and salvage renal function. The patient’s kidney function continued to deteriorate, progressing to end-stage kidney disease (ESKD) within 3 months of initial consult; therefore, hemodialysis was initiated.
The patient underwent multiple cycles of chemotherapy. However, due to recent hospitalizations for shortness of breath, pleural effusion, the need for symptom management, and several comorbidities, palliative care or hospice was recommended.
Discussion
Anti-TBM antibody nephritis is a rare immune-mediated disease associated with antibodies against a component of the TBM and characterized by progressive chronic tubulointerstitial injury with sparing glomeruli. The disease has been reported either as a primary phenomenon or in the context of other conditions.
Primary anti-TBM antibody disease is caused by an autoantibody against a protein called TIN-ag. 2 This antigen has been identified as a 58-kDa extracellular matrix non-collagenous protein restrictively expressed in the proximal TBM by Kanwar et al 4 and as 54-kDa protein with its gene mapped to chromosome 6p11.2-12 by Ikeda et al. 5 Although the function of this antigen is not yet completely understood, during embryonic life, TIN-ag is involved in tubulogenesis by promoting cell adhesion through interactions with type IV collagen and laminin. 5 - 7 In addition, TIN-ag serves as a ligand for integrins α3β1 and αVβ3, and thus, it is involved in maintaining the integrity of the kidney TBM. 8 The pathogenesis of anti-TBM antibody nephritis has not been clearly defined. It is unclear whether kidney damage is mediated directly by these antibodies or if kidney tubular damage is the initial insult that stimulates the development of the antibodies. 9 Several studies have used animal models to demonstrate the association of these antibodies with tubulointerstitial nephritis. Injection of anti-TBM antibodies from the sera of patients with anti-TBM disease has been demonstrated to cause typical findings of anti-TBM antibody nephritis in animal models. 9
Anti-TBM antibody nephritis has also been reported in association with other diseases or medications. The present case is the first report of anti-TBM antibody nephritis in a background of a lymphoplasmacytic neoplasm, whereas a literature review revealed no clear association between lymphoproliferative disorders and anti-TBM disease. However, given the phenomenon of paraneoplastic antibody production by some lymphoid malignancies and the temporal association of the 2 conditions in this patient, we suspect CLL may have contributed to the development of anti-TBM nephritis. Rifai et al 1 reported a case of anti-TBM nephritis in a patient receiving nivolumab infusions for the treatment of urothelial carcinoma with concurrent pyelonephritis. Border et al 10 described a patient developing anti-TBM antibody nephritis following receiving methicillin.
Similar to our case, the immunoglobulin detected in anti-TBM antibody nephritis is usually of the IgG class, although an example of pathogenic IgA anti-TBM antibodies is reported in the context of Goodpasture’s syndrome. 11
Clinical presentation often includes acute and chronic kidney dysfunction, polyuria, polydipsia, subnephrotic proteinuria, and microscopic hematuria. 9 Our case presented with elevated serum Cr, non-anion gap metabolic acidosis, glucosuria, and subnephrotic range proteinuria.
Table 1 provides a summary of reported anti-TBM cases, including the case presented in this report.
Table 1.
Summary of reported anti-TBM cases
Abbreviations: BCC, basal cell carcinoma; CLL, chronic lymphocytic leukemia; ESKD, end-stage kidney disease; GBM, glomerular basement membrane; IFTA, interstitial fibrosis and tubular atrophy; IV, intravenous; R-CVP, rituximab-cyclophosphamide, vincristine, prednisone; SPEP, serum protein electrophoresis; TBM, tubular basement membrane.
| Case | Age/sex | Medical history | Diagnosis | Initial/final creatinine | Serologic/immunological findings | Kidney biopsy | Immunofluorescence microscopy | Treatment | Outcome |
| Rifai AO, et al 1 | 71/male | High-grade urothelial carcinoma with lymphovascular invasion treated with gemcitabine and cisplatin followed by radical cystectomy and ileal conduit Ongoing nivolumab infusions for 16 months Atrial fibrillation treated with apixaban and benazepril | Acute kidney injury secondary to nivolumab therapy | Initial: 4.4 mg/dL Final: 9.6 mg/dL | Negative for ANA, ANCA, anti-GBM antibodies, anti-TBM antibodies | 17 glomeruli with 3 globally sclerotic; no mesangial or endocapillary hypercellularity, fibrinoid necrosis, or crescents; Moderate IFTA; dense interstitial inflammation with eosinophils, neutrophils, lymphocytes, plasma cells, histiocytes; neutrophil-rich inflammation with tubulitis | Strong linear IgG and C3 staining (3+ each) along the proximal TBM; no glomerular or distal tubular staining; IgG subclasses (IgG1, IgG2, IgG3, IgG4) positive along TBM (3+) No TBM deposits on electron microscopy | IV methylprednisolone, IV ceftriaxone, nivolumab discontinued, oral prednisone after discharge, hemodialysis | Gradual improvement in kidney function with cessation of hemodialysis Serologic remission with negative anti-TBM antibodies after steroid therapy and discontinuation of nivolumab Patient remained off dialysis post-treatment |
| Border WA, et al 10 | 29/male | Gunshot wound to the left thigh | Methicillin-induced acute interstitial nephritis | Initial: 1.6 mg/dL Final: 3.9 mg/dL | Negative skin tests for penicillin G, methicillin; negative for anti-methicillin/penicillin antibodies in hemagglutination test | Severe interstitial disease with essentially normal glomeruli and vessels; marked degeneration of tubules; inflammatory infiltrate with eosinophils and plasma cells | IgG and C3 in a linear pattern along TBM of cortical tubules; fibrin deposits in interstitium; no IgA/IgM deposits; methicillin antigen present along TBM; glomeruli negative for IgG, IgA, IgM, C3, and fibrin | Wound care, oral penicillin V, oxacillin, prednisone, methicillin discontinued, intermittent hemodialysis | Discharged to outpatient hemodialysis Persistent kidney impairment with diminished tubular function |
| Our case | 69/male | Hypertension Cutaneous BCC Prostatic adenocarcinoma treated with proton therapy and leuprolide CLL | Anti-tubular basement membrane antibody nephritis | Initial: 2.5 mg/dL Final: 3.6 mg/dL | Normal serum IgA, IgG, IgM; low C4; negative for ANA, anti-dsDNA, anti-GBM, cryoglobulins, and ANCA panel; IgG lambda light chain band on SPEP | 27 glomeruli, 7 obsolescent; focal mesangial expansion and segmental glomerulosclerosis; extensive IFTA (90% of cortex); mild interstitial edema, focal tubulitis, patchy lymphoplasmacytic inflammation | Linear staining of TBM for IgG, C3, and focal staining for C1q; no glomerular or Bowman’s basement membrane staining No immune deposits on electron microscopy | R-CVP chemotherapy regimen, filgrastim, hemodialysis | Progressed to ESKD and palliative care/hospice recommended due to multiple comorbidities |
In summary, anti-TBM antibody nephritis is an immune-mediated disease associated with antibodies against a component of the TBM and characterized by progressive chronic tubulointerstitial injury with sparing glomeruli. 2 There is currently no clearly defined specific treatment for this disorder, and management remains largely supportive. Anti-TBM antibody nephritis has been reported in kidney allograft in patients who did not have the antigen. 2
This case highlights the management challenges of anti-TBM antibody nephritis as a rare kidney disorder. Although the diagnosis was confirmed through a kidney biopsy, the primary challenge was preventing the disease from advancing to a severe stage, as the patient already had significant IFTA at the time of diagnosis. This emphasizes the importance of early diagnosis, even when treatment, such as chemotherapy for the presumed underlying condition, has been initiated.
This case also highlights the limited existing literature supporting a direct relationship between lymphoproliferative disorders and anti-TBM disease.
A more specific recommendation for future research would be to investigate whether underlying malignancies contribute to anti-TBM antibody nephritis or if patients with lower IFTA might benefit from immunosuppressive therapy to improve clinical outcomes. This targeted approach could provide clearer insights into immune-mediated kidney injury mechanisms and inform potential therapeutic interventions.
Authors’ Note: This case was previously presented as a poster at the American Society of Nephrology (ASN) Kidney Week, held in November 2016 in Chicago, Illinois.
The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: SN has received payments from Caliditas, Travere, Boehringer Ingelheim, and Otsuka in the past. The remaining authors declare that they have no relevant financial interests.
Funding: The author(s) received no financial support for the research, authorship, and/or publication of this article.
Ethics Approval: Our institution does not require ethical approval for reporting individual cases or case series.
Informed Consent: Verbal informed consent was obtained from the patient(s) for their anonymized information to be published in this article.
ORCID iD: Niloufar Ebrahimi https://orcid.org/0000-0003-2585-7820
References
1 Rifai AO Denig KM Caza T , et al . Antitubular basement membrane antibody disease associated with nivolumab infusion and concomitant acute pyelonephritis leading to acute kidney injury: a case report and literature review . Case Rep Nephrol . 2023 ; 2023 : 6681756 . doi: 10.1155/2023/6681756 37051373 PMC10085645
2 Lusco MA Fogo AB Najafian B Alpers CE. AJKD atlas of renal pathology: anti-tubular basement membrane antibody disease . Am J Kidney Dis . 2017 ; 70 ( 1 ):e3-e4. doi: 10.1053/j.ajkd.2017.05.001 28646985
3 Fogo AB Kashgarian M. Diagnostic Atlas of Renal Pathology . 3rd ed. Philadelphia, PA : Elsevier ; 2017 .
4 Kanwar YS Kumar A Yang Q , et al . Tubulointerstitial nephritis antigen: an extracellular matrix protein that selectively regulates tubulogenesis vs. Glomerulogenesis during mammalian renal development . Proc Natl Acad Sci U S A . 1999 ; 96 : 11323 - 11328 . doi: 10.1073/pnas.96.20.11323 10500175 PMC18032
5 Ikeda M Takemura T Hino S , et al . Molecular cloning, expression, and chromosomal localization of a human tubulointerstitial nephritis antigen . Biochem Biophys Res Commun . 2000 ; 268 : 225 - 230 . doi: 10.1006/bbrc.2000.2103 10652240
6 Kalfa TA Thull JD Butkowski RJ , et al . Tubulointerstitial nephritis antigen interacts with laminin and type IV collagen and promotes cell adhesion . J Biol Chem . 1994 ; 269 : 1654 - 1659 . 8294412
7 Kumar A Ota K Wada J , et al . Developmental regulation and partial-length cloning of tubulointerstitial nephritis antigen of murine metanephros . Kidney Int . 1997 ; 52 ( 3 ): 620 - 627 . doi: 10.1038/ki.1997.375 9291180
8 Wada J Kumar A Liu Z , et al . Cloning of mouse integrin alphaV cDNA and role of the alphaV-related matrix receptors in metanephric development . J Cell Biol . 1996 ; 132 ( 6 ): 1161 - 1176 . doi: 10.1083/jcb.132.6.1161 8601592 PMC2120751
9 Bergstein J Litman N. Interstitial nephritis with anti-tubular-basement-membrane antibody . N Engl J Med . 1975 ; 292 : 875 - 878 . doi: 10.1056/NEJM197504242921701 804130
10 Border WA Lehman DH Egan JD , et al . Antitubular basement-membrane antibodies in methicillin-associated interstitial nephritis . N Engl J Med . 1974 ; 291 : 381 - 384 . doi: 10.1056/nejm197408222910803 4211170
11 Border WA Baehler RW Bhathena D Glassock RJ. IgA antibasement membrane nephritis with pulmonary hemorrhage . Ann Intern Med . 1979 ; 91 ( 1 ): 21 - 25 . doi: 10.7326/0003-4819-91-1-21 111592